スイス料理 Swiss cooking Schweizer Küche Cuisine Suisse
In Switzerland where four different languages and cultures come together, there's an enormous variety in the cuisine.
You'll find classics like Bernese platter, Zurich-style veal ragout, papet vaudois (leeks and potatoes with sausage) or Graubünden nut and honey pie alongside new creations made with typical and innovative domestic products.
Designed fo rall operable patients suffering from a heart valve disease:
Novostia SA isa development stage company in the business of designing, manufacturing and marketing a revolutionary prosthetic heart valve known as the Lapeyre-Triflo Valve (“LTV”).
he LTV is a mechanical tri-leaflet heart valve that has the geometry and function similar to the human heart valve. It isdesigned to eradicate the need of lifelong anticoagulation therapy, behaving physiologically like a tissue valve, and to be resistant to structural failure(“one valve for life”).
The LTV is made of strong high performance bio compatible material (polymer, titanium, polyester). The surgical handling isidentical to current surgical heart valves.
Over twenty-five years of research with well-known research laboratories as well as with leaders in fluid mechanics and high precision manufacturers have led to this new concept of prosthetic heart valve.
Novostia is in pre-clinical phase and is working closely with key opinion leaders to prepare the clinical phase for this long-waited heart valve solution. However, the valve has not yet received CE Marking or FDA approval for commercialization.
The companyhas been incorporated on April 2017 and is based in Neuchatel, Switzerland.
Xeltis is a clinical-stage European medical device company leveraging breakthrough science to transform heart valve therapy. Xeltis is revolutionizing the treatment of heart valve disease. The company’s restorative heart valves enable the patient’s own body to naturally form a new heart valve through a therapeutic approach called Endogenous Tissue Restoration (ETR). With ETR, the patient’s natural healing system develops tissue that pervades Xeltis’ heart valve, forming a new, natural and fully functional valve within it. As ETR occurs, Xeltis implants are gradually absorbed by the body.
Xeltis has been granted permission by the US Food and Drug Association to begin its Xplore-II clinical trial for its pulmonary valve in the United States.
The company Xeltis AG was founded June 2006 and is based in Zurich, Switzerland.